Well Referenced

Tag: Infectious Diseases

Timely Use of Probiotics in Hospitalized Adults Prevents Clostridium difficile Infection: A Systematic Review With Meta-Regression Analysis

In this 2017 systematic review and meta-regression analysis published in Gastroenterology, Shen et al. evaluated the efficacy of probiotics in preventing Clostridium difficile infection (CDI) among hospitalized adults receiving antibiotics. Analyzing data from 19 randomized controlled trials encompassing over 6,000 patients, the study found that probiotic administration significantly reduced the

Read More »
June 26, 2025 No Comments

Vitamin supplementation of HIV-infected women improves postnatal child growth

This randomized, double-blind, placebo-controlled trial conducted in Dar es Salaam, Tanzania, assessed the impact of maternal vitamin supplementation on the growth of children born to HIV-infected women. A total of 1,078 HIV-positive pregnant women were enrolled and randomized to receive daily supplements of multivitamins (vitamins B, C, and E), vitamin

Read More »
June 26, 2025 No Comments

Ivermectin for preventing and treating COVID-19

This comprehensive Cochrane systematic review, updated in June 2022, critically evaluated randomized controlled trials assessing ivermectin’s efficacy and safety for COVID-19 prevention and treatment. The analysis incorporated studies involving both hospitalized and outpatient populations with varying disease severities. Despite initial in vitro findings suggesting antiviral properties, the review found no

Read More »
June 26, 2025 No Comments

Effect of Early Treatment with Ivermectin among Patients with Covid-19

This multicenter, double-blind, randomized, placebo-controlled trial assessed whether early administration of ivermectin could prevent hospitalization or extended emergency observation in high-risk outpatients with COVID-19. Conducted across 12 public health clinics in Brazil, the study enrolled 3,515 symptomatic adults within 7 days of symptom onset, all possessing at least one risk

Read More »
June 26, 2025 No Comments

Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities: The I-TECH Randomized Clinical Trial

This multicenter, double-blind, randomized controlled trial evaluated the efficacy of oral ivermectin in preventing disease progression among adults with mild to moderate COVID-19 and existing comorbidities. Participants were randomly assigned to receive either ivermectin or a placebo, and outcomes such as hospitalization rates, symptom resolution, and adverse events were monitored.

Read More »
June 26, 2025 No Comments

Efficacy and safety of oral ivermectin in the treatment of mild to moderate Covid-19 patients: a multi-centre double-blind randomized controlled clinical trial

This multicenter, double-blind, randomized controlled trial evaluated the efficacy and safety of oral ivermectin in treating patients with mild to moderate COVID-19. Participants were assigned to receive either ivermectin or a placebo, and outcomes such as symptom resolution, viral clearance, hospitalization rates, and adverse events were monitored. The study found

Read More »
June 26, 2025 No Comments

Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19

This 2024 open-label pilot study, published in Brain, Behavior, and Immunity – Health, evaluated the combined use of low-dose naltrexone (LDN) and nicotinamide adenine dinucleotide (NAD+) in treating persistent fatigue symptoms in post-COVID-19 patients. Conducted by researchers from AgelessRx and the University of Pittsburgh, the study involved 36 participants experiencing

Read More »
June 26, 2025 No Comments

Low-dose naltrexone use for the management of post-acute sequelae of COVID-19

This 2023 study, published in International Immunopharmacology, investigates the potential of low-dose naltrexone (LDN) in treating post-acute sequelae of COVID-19 (PASC), commonly known as long COVID. The researchers explored LDN’s immunomodulatory effects, particularly its ability to reduce neuroinflammation and modulate immune responses, which are believed to contribute to long COVID

Read More »
June 26, 2025 No Comments

Nicotinamide Riboside—The Current State of Research and Therapeutic Uses

This comprehensive review delves into the multifaceted role of nicotinamide riboside (NR), a form of vitamin B3, as a potent precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme integral to numerous metabolic processes. The authors discuss how NR supplementation has been shown to elevate NAD+ levels, thereby enhancing mitochondrial function

Read More »
June 26, 2025 No Comments

BPC 157 as Potential Treatment for COVID-19

This hypothesis article explores the potential application of BPC 157, a synthetic peptide derived from human gastric juice, as a therapeutic agent for COVID-19. BPC 157 is known for its cytoprotective and anti-inflammatory properties, which may be beneficial in mitigating the systemic inflammation and multi-organ damage associated with severe COVID-19.

Read More »
June 26, 2025 No Comments